Quantum Biopharma Ltd. Class B Subordinate Voting Shares
QNTM
About: Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Employees: 7
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
330% more capital invested
Capital invested by funds: $553K [Q1] → $2.37M (+$1.82M) [Q2]
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
21% more funds holding
Funds holding: 14 [Q1] → 17 (+3) [Q2]
0.18% more ownership
Funds ownership: 3.64% [Q1] → 3.82% (+0.18%) [Q2]
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Financial journalist opinion
